keyword
MENU ▼
Read by QxMD icon Read
search

New treatment in HCV

keyword
https://www.readbyqxmd.com/read/28715911/hepatitis-c-treatment-regimens-are-cost-effective-but-compared-with-what
#1
T Joseph Mattingly, Julia F Slejko, C Daniel Mullins
BACKGROUND: Numerous economic models have been published evaluating treatment of chronic hepatitis C virus (HCV) infection, but none provide a comprehensive comparison among new antiviral agents. OBJECTIVE: Evaluate the cost-effectiveness of all recommended therapies for treatment of genotypes 1 and 4 chronic HCV. METHODS: Using data from clinical trials, observational analyses, and drug pricing databases, Markov decision models were developed for HCV genotypes 1 and 4 to compare all recommended drugs from the perspective of the third-party payer over a 5-, 10-, and 50-year time horizon...
July 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28714143/efficacy-and-safety-of-new-direct-antiviral-agents-in-hcv-infected-patients-with-diffuse-large-b-cell-non-hodgkin-lymphoma
#2
Marcello Persico, Andrea Aglitti, Rosa Caruso, Amalia De Renzo, Carmine Selleri, Catello Califano, Ludovico Abenavoli, Alessandro Federico, Mario Masarone
INTRODUCTION: The association of HCV with Non-Hodgkin Lymphoma (NHL) has been demonstrated all over the world. The new interferon-free, direct antiviral agents (DAA), showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not -and how- to treat the HCV positive patients suffering from diffuse large B cell lymphomas(DLBCL). Aim of this observational study was to evaluate whether the DAAs antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a safe and effective option...
July 17, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28710214/trends-and-factors-in-human-immunodeficiency-virus-and-or-hepatitis-c-virus-testing-and-infection-among-injection-drug-users-newly-entering-methadone-maintenance-treatment-in-guangdong-province-china-2006-2013-a-consecutive-cross-sectional-study
#3
Yin Liu, Yu Liu, Xia Zou, Wen Chen, Li Ling
OBJECTIVES: To assess trends and related factors in HIV and/or hepatitis C virus (HCV) antibody testing and infection among injection drug users (IDUs) newly entering methadone maintenance treatment (MMT) in Guangdong Province, China. METHOD: Consecutive cross sectional surveys were conducted in 14 MMT clinics from July 2006 to December 2013 in Guangdong Province, China. IDUs were excluded if they were re-enrolled or referred from other MMT clinics. Trend tests were used to examine HIV and/or HCV testing and infection, sociodemographic characteristics, drug use related behaviours and the past 3 month sexual behaviours on enrolment...
July 13, 2017: BMJ Open
https://www.readbyqxmd.com/read/28699096/hepatitis-c-cascade-of-care-among-pregnant-women-on-opioid-agonist-pharmacotherapy-attending-a-comprehensive-prenatal-program
#4
Kimberly Page, Lawrence Leeman, Steven Bishop, Sandra Cano, Ludmila N Bakhireva
Background Given the large increases in opioid use among pregnant women and associations with hepatitis C virus (HCV) infection, screening pregnant women who are on (opioid agonist) pharmacotherapy for HCV infection has potential to inform medical care for these mothers as well as their newborns. We investigated the HCV testing cascade among pregnant women on pharmacotherapy in order to describe exposure and infection rates and to identify opportunities that would improve care. Methods Secondary analyses of laboratory results were performed for HCV testing, including anti-HCV, viremia (RNA) and genotype...
July 11, 2017: Maternal and Child Health Journal
https://www.readbyqxmd.com/read/28689856/restrictions-on-access-to-direct-acting-antivirals-for-people-who-inject-drugs-the-european-hep-core-study-and-the-role-of-patient-groups-in-monitoring-national-hcv-responses
#5
J V Lazarus, K Safreed-Harmon, S R Stumo, M Jauffret-Roustide, M Maticic, T Reic, E Schatz, J Tallada, M Harris
In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from the hepatitis C virus (HCV) by 2030. If European countries are to come close to reaching the WHO targets, they must squarely address the HCV prevention, testing and treatment needs of people who inject drugs (PWID). This viewpoint reports on findings from the 2016 European Hep-CORE study, which was unique in its utilisation of patient groups as a source of hepatitis policy information...
July 6, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28689585/rheumatologic-manifestations-of-hepatitis-c-virus-infection
#6
REVIEW
Patrice Cacoub, Cloé Comarmond, Anne Claire Desbois, David Saadoun
Hepatitis C virus (HCV) infection is associated with a morbidity and mortality due to liver complications. HCV infection is also frequently associated with rheumatic disorders, such as arthralgia, myalgia, cryoglobulinemia vasculitis, and sicca syndrome, as well as the production of autoantibodies. The treatment of HCV infection with interferon alpha (IFN) has been contraindicated for a long time in many rheumatologic autoimmune/inflammatory disorders. New oral IFN-free combinations offer an opportunity for HCV-infected patients with extrahepatic manifestations, including rheumatologic autoimmune/inflammatory disorders, to be cured with a short treatment duration and a low risk of side effects...
August 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/28687477/prognostic-factors-and-predictors-of-sorafenib-benefit-in-patients-with-hepatocellular-carcinoma-analysis-of-two-phase-3-studies
#7
Jordi Bruix, Ann-Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Josep Llovet
BACKGROUND AND AIMS: Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival (OS) versus placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase 3 studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia-Pacific (AP). To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we conducted a pooled exploratory analysis from these placebo-controlled phase 3 studies. METHODS: To identify potential prognostic factors for OS, univariate and multivariate (MV) analyses were performed for baseline variables by Cox proportional hazards model...
July 4, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28675071/from-the-pathogenesis-to-the-cure-of-indolent-b-cell-lymphoproliferative-disorders-associated-with-hepatitis-c-virus-infection-which-role-for-direct-acting-antivirals
#8
Marcella Visentini, Massimo Fiorilli, Milvia Casato
Hepatitis C virus (HCV) causes monoclonal B cell lymphoproliferative disorders ranging from benign, such as in mixed cryoglobulinemia (MC), to indolent or aggressive lymphomas. MC and indolent lymphomas commonly regress when HCV is eradicated with interferon (IFN) therapy; however, sustained virologic response (SVR) to IFN is achieved only in ~50% of patients. The new all oral direct-acting antivirals (DAA), yielding nearly 100% SVR, promise a breakthrough in the treatment of HCV-associated lymphoproliferative disorders, but experience is still scanty...
July 4, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28673800/modeling-hcv-cure-after-an-ultra-short-duration-of-therapy-with-direct-acting-agents
#9
Ashish Goyal, Yoav Lurie, Eric G Meissner, Marian Major, Natasha Sansone, Susan L Uprichard, Scott J Cotler, Harel Dahari
BACKGROUND: Cases of sustained-virological response (SVR or cure) after an ultra-short duration (≤27 days) of direct-acting antiviral (DAA)-based therapy, despite HCV being detected at end of treatment (EOT), have been reported. Established HCV mathematical models that predict the treatment duration required to achieve cure do not take into account the possibility that the infectivity of virus produced during treatment might be reduced. The aim of this study was to develop a new mathematical model that considers the fundamental and critical concept that HCV RNA in serum represents both infectious virus (Vi) and non-infectious virus (Vni) in order to explain the observation of cure with ultrashort DAA therapy...
June 30, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28673437/-i-didn-t-want-to-let-it-go-too-far-the-decisions-and-experiences-of-people-who-inject-drugs-who-received-a-liver-disease-assessment-as-part-of-a-liver-health-promotion-campaign-the-liverlife-study
#10
Alison D Marshall, Jason Grebely, Gregory J Dore, Carla Treloar
BACKGROUND: An open cohort study (LiveRLife) evaluating an intervention integrating non-invasive liver disease assessment via transient elastography (TE) among people who inject drugs (PWID) was conducted in New South Wales, Australia. Participant follow-up occurred 2-16 weeks post-enrolment. It is imperative that PWID understand liver assessment results in order to make informed decisions about their health. The aim of this study was to evaluate the decisions and experiences of participants who received a liver disease assessment, including interpretation of TE score and subsequent health behaviours, using a health literacy framework...
June 30, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28666636/high-hepatitis-c-incidence-in-relation-to-prescription-opioid-injection-and-poly-drug-use-assessing-barriers-to-hepatitis-c-prevention
#11
Svetlana Puzhko, Élise Roy, Didier Jutras-Aswad, Andreea Adelina Artenie, Emmanuel Fortier, Geng Zang, Julie Bruneau
BACKGROUND: Prescription opioid (PO) injection and poly-drug use have been associated with hepatitis C virus (HCV) infection among people who inject drugs (PWID). Poly-drug use is often a barrier to key HCV preventive programmes including opioid agonist treatment. The contribution of specific drug combinations to high HCV incidence in poly-drug users has not been assessed previously. Addressing this knowledge gap could enhance HCV treatment and prevention efforts. We examined the association between specific drugs and number of drugs used in addition to injected POs, and HCV seroconversion...
June 27, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28662284/estimate-of-vertical-transmission-of-hepatitis-c-virus-in-pakistan-in-2007-and-2012-birth-cohorts
#12
Lenka Benova, Susanne Faissal Awad, Laith Jamal Abu-Raddad
Despite a combination of high Hepatitis C virus (HCV) prevalence, a large adult population and high fertility, no published estimates of the scale and contribution of vertical transmission to HCV incidence in Pakistan exist. The objective of this study was to estimate the number of new HCV infections occurring in Pakistan as a result vertical transmission. We adapted a published mathematical model based on HCV antibody and viremia prevalence, fertility rates, risk of HCV vertical transmission and children mortality rates to estimate the number of infections in the 2007 and 2012 birth cohorts nationally and in four sub-national regions...
June 29, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28662105/discrepancies-in-prevalence-trends-for-hiv-hepatitis-b-virus-and-hepatitis-c-virus-in-haiphong-vietnam-from-2007-to-2012
#13
Azumi Ishizaki, Vuong Thi Tran, Cuong Hung Nguyen, Tomoaki Tanimoto, Huyen Thi Thanh Hoang, Hung Viet Pham, Chung Thi Thu Phan, Xiuqiong Bi, Thuc Van Pham, Hiroshi Ichimura
We previously reported a significant reduction in the prevalence of human immunodeficiency virus type 1 (HIV) from 2007 to 2012 in people who inject drugs (PWID; 35.9% to 18.5%, p < 0.001) and female sex workers (FSW; 23.1% to 9.8%, p < 0.05), but not in blood donors (BD) or pregnant women, in Haiphong, Vietnam. Our aim in the present study was to assess trends in the prevalence of infection with hepatitis B and C viruses (HBV and HCV, respectively). We also investigated the coinfection rates of HBV and HCV with HIV in the same groups...
2017: PloS One
https://www.readbyqxmd.com/read/28661549/hepatitis-c-in-pregnancy-review-of-current-knowledge-and-updated-recommendations-for-management
#14
Charlotte M Page, Brenna L Hughes, Eleanor H J Rhee, Jeffrey A Kuller
Importance: An estimated 1% to 2.5% of pregnant women in the United States are infected with hepatitis C virus (HCV), which carries approximately a 6% risk of mother-to-infant transmission. Objectives: The aims of this article are to review the current evidence on HCV in pregnancy and to provide updated recommendations for management. Evidence Acquisition: Original research articles, review articles, and guidelines on HCV in general and specifically in pregnancy were reviewed, as were drug safety profiles from the Food and Drug Administration...
June 2017: Obstetrical & Gynecological Survey
https://www.readbyqxmd.com/read/28647161/dot-c-a-cluster-randomised-feasibility-trial-evaluating-directly-observed-anti-hcv-therapy-in-a-population-receiving-opioid-substitute-therapy-from-community-pharmacy
#15
Andrew Radley, Jan Tait, John F Dillon
BACKGROUND: Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much smaller burden of treatment than interferon-based regimes, require less monitoring and are very effective. New pathways are required to increase access to treatment amongst people prescribed opioid substitution therapy (OST). METHODS: An exploratory cluster randomised controlled trial with mixed methods evaluation was undertaken to compare the uptake of dried blood spot testing (DBST) and treatment of people with genotype 1 HCV infection in a conventional service pathway versus a pharmacist-led pathway in a population receiving OST...
June 21, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28644739/treatment-of-hepatitis-c-with-new-fixed-dose-combinations
#16
Vicente Soriano
The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%. However, a subset of patients remains at higher risk for treatment failure, including those infected with: i) genotype 3 and cirrhosis; ii) resistance-associated substitutions (RAS) occurring either as natural polymorphisms or selected after prior DAA failure; and iii) poor drug adherence associated with social disabilities (homeless, psychiatric illnesses, injection drug use, alcoholism, etc...
June 23, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28642806/the-efficacy-of-epigallocatechin-3-gallate-green-tea-in-the-treatment-of-alzheimer-s-disease-an-overview-of-pre-clinical-studies-and-translational-perspectives-in-clinical-practice
#17
REVIEW
Marco Cascella, Sabrina Bimonte, Maria Rosaria Muzio, Vincenzo Schiavone, Arturo Cuomo
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia characterized by cognitive and memory impairment. One of the mechanism involved in the pathogenesis of AD, is the oxidative stress being involved in AD's development and progression. In addition, several studies proved that chronic viral infections, mainly induced by Human herpesvirus 1 (HHV-1), Cytomegalovirus (CMV), Human herpesvirus 2 (HHV-2), and Hepatitis C virus (HCV) could be responsible for AD's neuropathology...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28634131/cost-effectiveness-of-pre-versus-post-liver-transplant-hepatitis-c-treatment-with-direct-acting-antivirals
#18
Sumeyye Samur, Brian Kues, Turgay Ayer, Mark S Roberts, Fasiha Kanwal, Chin Hur, Drew Michael S Donnell, Raymond T Chung, Jagpreet Chhatwal
BACKGROUND & AIMS: Oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV) treatment offer new hope to both pre- and post-liver transplant (LT) patients. However, whether to treat HCV patients pre- versus post-LT is not clear, as treatment can improve liver function but could reduce the chance of receiving a LT while on the waiting list. Our objective was to evaluate the cost-effectiveness of pre-LT versus post-LT HCV treatment with oral DAAs in decompensated cirrhotic patients on the LT waiting list...
June 17, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28631044/-personalized-treatment-of-viral-hepatitis-of-the-present-and-the-future-hepatitis%C3%A2-b-c-delta-and-e
#19
REVIEW
R Bartenschlager, M Cornberg, T Pietschmann
Precision medicine is also possible for infectious diseases as shown for the treatment of chronic viral hepatitis, especially if different options are available. In hepatitis B virus (HBV) infection, treatment indication as well as the choice of treatment and the decisions to stop treatment are based on viral markers and alanine aminotransferase (ALT) level. Future therapies for HBV infection aiming for functional cure or even virus elimination may be even more personalized and have to take into account the immune status of a given patient...
June 19, 2017: Der Internist
https://www.readbyqxmd.com/read/28623451/neighborhood-inequalities-in-hepatitis-c-mortality-spatial-and-temporal-patterns-and-associated-factors
#20
Mary M Ford, Payal S Desai, Gil Maduro, Fabienne Laraque
Deaths attributable to hepatitis C (HCV) infection are increasing in the USA even as highly effective treatments become available. Neighborhood-level inequalities create barriers to care and treatment for many vulnerable populations. We seek to characterize citywide trends in HCV mortality rates over time and identify and describe neighborhoods in New York City (NYC) with disproportionately high rates and associated factors. We used a multiple cause of death (MCOD) definition for HCV mortality. Cases identified between January 1, 2006, and December 31, 2014, were geocoded to NYC census tracts (CT)...
June 16, 2017: Journal of Urban Health: Bulletin of the New York Academy of Medicine
keyword
keyword
36135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"